Intuitive Surgical Shares Fell After Earnings Despite 22% Revenue Growth

Intuitive Surgical shares fell after earnings

Intuitive Surgical shares traded on Nasdaq fell after the surgical-robotics company reported earnings on Oct. 20, despite revenue increasing 22%. The reviewed reporting does not establish whether the move was an intraday or closing decline, and the quoted share-price figures use different currencies and contexts.

One market update reported an after-hours decline of about 7% following the third-quarter results. A separate Nov. 1 market display showed the shares at 386.75 euros, down 3.60%, but did not identify the relevant trading session in the supplied passage. These figures should not be treated as directly comparable measurements of the same move.

The reported operating results

Intuitive Surgical generated $3.05 billion in revenue for the third quarter and earned $3 per share excluding certain items. The reviewed reporting describes the earnings as failing to impress investors, although it does not provide the corresponding forecast or a detailed explanation for the reaction.

The 22% year-over-year revenue increase was reported alongside growth in da Vinci system use. Procedures involving a da Vinci system rose 15%, while the installed base increased 12% year over year. Intuitive Surgical also sold more da Vinci systems in the third quarter of 2026 than in the corresponding quarter of 2025.

Installed systems underpin the revenue mix

Robots account for roughly 25% of Intuitive Surgical’s revenue, while instruments, accessories, parts and services make up the remainder, according to the reviewed commentary. More than 12,000 installed systems were cited as the basis for recurring revenue associated with the installed base.

That relationship is important to the market interpretation under review: system placements expand the installed base, while procedures and associated instruments, accessories and services contribute most of the company’s top line. The sources characterize the installed base as producing an annuity-like stream of revenue, but they do not disclose the economics or cash received from individual customers.

Competition remained the central investor concern

The commentary identified rising competition in surgical robotics as a material concern for Intuitive Surgical’s growth prospects. Medtronic and Johnson & Johnson had entered the market with devices that compete with the da Vinci system, and the analysis suggested that the established medical-device companies could gain traction.

At the same time, the reported increase in third-quarter da Vinci system sales and procedure growth indicated that the business continued growing despite those entrants. The reviewed sources attributed the share-price reaction to investor concerns, but they did not establish a company-confirmed causal explanation or quantify the competitive effect on orders, revenue or earnings.

The stock had recovered after the initial decline

The market commentary noted that Intuitive Surgical’s stock had recovered from the earnings-related drop and then some by Nov. 1. The available reporting therefore presented a decline after the Oct. 20 results, followed by a recovery, rather than a continuous fall through the coverage date.

No target price, valuation multiple, future earnings estimate or further scheduled filing was established in the reviewed sources.